E2F3 and central nervous system cancer: The findings suggested that miR-128-1 could impede the growth of glioblastoma and GSCs via targeting BMI1 and E2F3, so miR-128-1 and DNA demethylating agents were promising for anti-glioma therapy at least in part by eliminating GSCs [21].